medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 12

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (12)

Tumor markers in breast cancer. Systematic review

Bonilla-Sepúlveda ÓA

Language: Spanish
References: 55
Page: 860-869
PDF size: 191.37 Kb.


ABSTRACT

Background: Breast cancer is the most frequent malignant tumor in women around the world. The FDA-approved tumor markers are cancer antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA), and are frequently used for the detection and control of breast cancer.
Objective: To present the current available information on the usefulness of tumor markers CA 15-3 and carcinoembryonic antigen in the detection of metastases and their prognostic value in breast cancer.
Methodology: A systematic search of publications in English in the Medline- PubMed database was performed, using the terms: “biomarkers”, “tumor”, “tumor biomarkers”, “marker”, “tumor marker”, “breast neoplasms “,” breast “,” neoplasms “,” cancer “,” mucin-1 “,” ca 15 3 “,” carcinoembryonic antigen “. Original articles, clinical trials, reviews, systematic reviews and meta-analyzes, published between March 28, 2015 and March 25, 2020, were selected to determine the usefulness of the CA 15-3 antigen and carcinoembryonic antigen in breast cancer.
Results: Eleven publications that were relevant to determine the usefulness of tumor markers in breast cancer were selected for the writing of this article.
Conclusions: The utility of tumor markers Antigen 15-3 and carcinoembryonic antigen is contradictory, and not fully accepted by oncology associations and international guidelines, however there is evidence that confirms their utility as diagnostic and prognostic markers in breast cancer.


REFERENCES

  1. Cancer today. http://gco.iarc.fr/today/home.

  2. Redig A, McAllister S. Breast cancer as a systemic disease: a view of metastasis. J. Intern. Med. 2013; 274:113-26. doi: 10.1111/joim.12084.

  3. Sundquist M, et al. Improved survival in metastatic breast cancer 1985-2016, Breast. 2016; 31:46-50. doi: 10.1016/j. breast.2016.10.005.

  4. Taplin S, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst. 2008; 100 (12): 876-87. doi. 10.1093/jnci/djn172.

  5. Mandelblatt JS, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009; 151 (10): 738-47. doi. 10.7326/0003-4819-151-10-200911170- 00010.

  6. Duffy M. Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem. 2006; 52: 345-51. doi. 10.1373/ clinchem.2005.059832.

  7. Molina R, et al. Tumor markers in breast cancer -European Group on Tumor Markers recommendations. Tumour Biol. 2005; 26: 281-93. doi. 10.1159/000089260.

  8. Cheung K, et al. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 2000; 26: 91-102. doi. 10.1053/ctrv.1999.0151.

  9. Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007; 25: 5287-312. doi. 10.1200/JCO.2010.33.7311.

  10. Thompson JA, et al. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991; 5 (5): 344-66. doi. 10.1002/jcla.1860050510.

  11. Sulekha Dhanisha S, et al. Mucins: structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Crit Rev Oncol Hematol. 2017; 122: 98-122. doi. 10.1016/j.critrevonc.2017.12.006.

  12. Kufe D, et al. Differential reactivity of a novel monoclonal antibody (df3) with human malignant versus benign breast tumors. Hybridoma. 1984; 3 (3): 223-32. doi. 10.1089/ hyb.1984.3.223.

  13. Hayes DF, et al. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Investig. 1985; 75 (5): 1671-78. doi. 10.1172/JCI111875.

  14. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001; 6 (3): 339-53. doi. 10.1023/a:1011379725811.

  15. Roy LD, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011; 30 (12): 1449-59. doi. 10.1038/ onc.2010.526.

  16. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004; 4: 45. doi. 10.1038/nrc1251.

  17. Haddon L, Hugh J. MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/ Src signaling triad. Clin Exp Metas. 2015; 32 (4): 393-403. doi. 10.1007/s10585-015-9711-8.

  18. Wei X, et al. MUC1 oncoprotein stabilizes and activates estrogen receptor α. Mol Cell. 2006; 21 (2): 295-305. doi: 10.1016/j.molcel.2005.11.030.

  19. Merikhian P, et al. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Rev Anticancer Ther. 2017; 17 (7): 607-13. doi. 10.1080/14737140.2017.1340837.

  20. Lin DC, Genzen JR. Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. Breast Cancer Res Treat. 2018; 167 (1): 269-76. doi.10.1007/s10549-017- 4513-0

  21. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965; 21: 439-62. doi. 10.1084/jem.121.3.439.

  22. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999; 9 (2): 67-81. doi. 10.1006/scbi.1998.0119.

  23. Charbonneau J, Stanners CP. Role of carbohydrate structures in CEA-mediated intercellular adhesion. Cell Adhes Commun. 1999; 7 (3): 233-44. doi: 10.3109/15419069909010805.

  24. Kabel AM. Tumor markers of breast cancer: new prospective. J Oncol Sci. 2017; 3 (1): 5-11. doi: 10.1016/j. jons.2017.01.001.

  25. Stern N, et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol. 2005; 174 (11): 6692-701. doi: 10.4049/jimmunol.174.11.6692.

  26. Nicolini A, Carpi A. Postoperative follow‐up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol. 2000; 21 (4): 235‐48. doi: 10.1159/000030129.

  27. O’Hanlon DM, et al. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer. 1995; 71 (6): 1288-91. doi: 10.1038/bjc.1995.249.

  28. Uehara M, et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 2008; 13 (5): 447-51. doi: 10.1007/s10147-008-0773-3.

  29. Maric P, et al. Tumor markers in breast cancer -evaluation of their clinical usefulness. Coll Antropol. 2011; 35: 241-47. PMID: 21661378.

  30. Cardoso F, et al. Inconsistent criteria used in American Society of Clinical Oncology 2007. Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2008; 26: 2058-59. doi: 10.1200/JCO.2007.15.6638.

  31. NCCN guidelines Version 4. 2018 Breast cancer 2018. https ://www.nccn.org/profe ssion als/physi cian_ gls/pdf/ breas t_block s.pdf.

  32. Largillier J, et al. Prognostic factors in 1038 women with metastatic breast cancer, Ann. Oncol. 2008; 19: 2012-19. doi: 10.1093/annonc/mdn424.

  33. Mosconi P, et al. Survival, quality of life and breast cancer. Ann. Oncol. 2001; 12: S15-S19. doi: 10.1093/annonc/12. suppl_3.s15.

  34. Stieber P, et al. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer. A retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta. 2015; 448: 228-31. doi:10.1016/j.cca.2015.06.022.

  35. Shao Y, et al. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015; 10 (7): e0133830. doi:10.1371/journal.pone.0133830.

  36. Wu S, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014; 23: 88-93. doi: 10.1016/j. breast.2013.11.003.

  37. Tomlinson I, et al. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur. J. Cancer. 1995; 31A: 899-902. doi: 10.1016/0959-8049(94)00447-1.

  38. Soletormos G, et al. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur. J. Cancer. 2004; 40: 481-86. doi: 10.1016/j.ejca.2003.10.015.

  39. Colomer R, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in nonmalignant diseases. Breast Cancer Res. Treat. 1989; 13: 123-33. doi: 10.1007/BF01806524.

  40. Guadagni F, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin. Cancer Res. 2001; 7: 2357-62. PMID: 11489813.

  41. Jager W, et al. Breast cancer and clinical utility of CA 15-3 and CEA. Scand. J. Clin. Lab. Invest. Suppl. 1995; 221: 87-92. doi: 10.3109/00365519509090570.

  42. Al-Jarallah M, et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur. J. Surg. Oncol. 1993; 19: 74-79. PMID: 8436243.

  43. Engel K, et al. CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer. Geburtshilfe Frauenheilkd. 1988; 48: 309-12. doi: 10.1055/s-2008-1026508.

  44. Coveney E, et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int. J. Biol. Markers. 1995; 10: 35-41. PMID: 7629425.

  45. Ertl I, et al. CA125 in the early detection of metastatic breast cancer. http://ascopubs.org/doi/abs/10.1200/ jco.2009.27.15s.e12015.

  46. Van Poznak C, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology. Clinical Practice Guidelines. J Clin Oncol. 2015; 33 (24): 2695-704. doi: 10.1200/JCO.2015.61.1459.

  47. Li X, et al. Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: A meta-analysis including 12,993 patients. Dis Markers. 2018; 2018: 9863092. doi: 10.1155/2018/9863092.

  48. Fu Y, Li H. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis. Med Sci Monit. 2016;22:3154-62. doi: 10.12659/msm.896563.

  49. Di Gioia D, Blankenburg I, Nagel D, Heinemann V, Stieber P. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clin Chim Acta. 2016;461:1-7. doi: 10.1016/j. cca.2016.07.014.

  50. Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao X, Jing J. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017;470:51-55. doi: 10.1016/j. cca.2017.04.023.

  51. Fujimoto Y, Higuchi T, Nishimukai A, Miyagawa Y, Kira A, Ozawa H, Bun A, Imamura M, Miyoshi Y. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. J Surg Oncol. 2018;118(1):228-237. doi: 10.1002/jso.25125.

  52. Nicolini A, Carpi A, Ferrari P, Morganti R, Mazzotti V, Barak V, Duffy MJ. An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag Res. 2018;10:6879-6886. doi: 10.2147/CMAR.S177522.

  53. Bayo J, Castaño MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. Clin Transl Oncol. 2018;20(4):467-475. doi: 10.1007/s12094-017-1731-1.

  54. Imamura M, et al. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol. 2018; 16 (1): 26. doi. 10.1186/s12957-018- 1325-6.

  55. Nam SE, et al. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Breast Cancer Res Treat. 2019; 177 (3): 669-78. doi. 10.1007/s10549-019-05357-y.




2020     |     www.medigraphic.com